The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AVXL | -57.59% | -28.68% | -6.53% | +5,645% |
| S&P | +14.18% | +88.25% | +13.47% | +431% |
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
The company generates no revenue, but it may be worth taking a chance on as it possesses lots of upside.
The company's first-quarter earnings report detailed positive news regarding its pipeline.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $764.45M | 58.7% |
| Market Cap / Employee | $22.48M | 0.0% |
| Employees | 34 | -19.0% |
| Net Income | -$9.83M | 15.4% |
| EBITDA | -$10.84M | 24.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $102.58M | -22.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -38.75% | -9.1% |
| Return On Invested Capital | -44.91% | 18.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$8.60M | -29.2% |
| Operating Free Cash Flow | -$8.60M | -29.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 7.57 | 6.57 | 7.89 | 8.36 | 125.35% |
| Price to Tangible Book Value | 7.57 | 6.57 | 7.89 | 8.36 | 125.35% |
| Enterprise Value to EBITDA | -58.13 | -49.08 | -47.45 | -61.04 | 150.40% |
| Return on Equity | -37.7% | -40.1% | -43.6% | -43.1% | 31.40% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
AVXL earnings call for the period ending June 30, 2022.
AVXL earnings call for the period ending March 31, 2022.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
